Translate Bio (TBIO) Gets a Buy Rating from William Blair

William Blair analyst Myles Minter reiterated a Buy rating on Translate Bio (TBIO – Research Report) yesterday. The company's shares closed last Friday at $18.36. According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences. Translate Bio has an analyst consensus of Moderate Buy, with a price target consensus of $22.67. See today’s analyst top recommended stocks >> Translate Bio's market cap is currently $1.41B and has a P/E ratio of -68.10. The company has a Price to Book ratio of 5.29. Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TBIO in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. The post Translate Bio (TBIO) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

William Blair analyst Myles Minter reiterated a Buy rating on Translate Bio (TBIO – Research Report) yesterday. The company's shares closed last Friday at $18.36.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.2% and a 62.7% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Translate Bio has an analyst consensus of Moderate Buy, with a price target consensus of $22.67.

Translate Bio's market cap is currently $1.41B and has a P/E ratio of -68.10. The company has a Price to Book ratio of 5.29.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

The post Translate Bio (TBIO) Gets a Buy Rating from William Blair appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

William Blair Reaffirms Their Buy Rating on Phasebio Pharmaceuticals (PHAS)

In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report). The company's shares closed last Friday at $3.75. According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Autolus Therapeutics, and Chinook Therapeutics. Phasebio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.67, representing a 243.6% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $8.00 price target. See today’s analyst top recommended stocks >> Phasebio Pharmaceuticals' market cap is currently $190.8M and has a P/E ratio of -1.10. The company has a Price to Book ratio of 22.52. Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAS in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA. The post William Blair Reaffirms Their Buy Rating on Phasebio Pharmaceuticals (PHAS) appeared first on TipRanks Financial Blog.

In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report). The company's shares closed last Friday at $3.75.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Autolus Therapeutics, and Chinook Therapeutics.

Phasebio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.67, representing a 243.6% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $8.00 price target.

Phasebio Pharmaceuticals' market cap is currently $190.8M and has a P/E ratio of -1.10. The company has a Price to Book ratio of 22.52.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

The post William Blair Reaffirms Their Buy Rating on Phasebio Pharmaceuticals (PHAS) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.